CAMP4 TherapeuticsCAMP
Recorded

CAMP4 Therapeutics 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration24 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Matthew TanBiotech Equity Research Associate

Hey, everyone. I'm Matthew, and I'm pleased to be joined here today by CEO of CAMP4 Therapeutics, Josh Mandel-Brehm. Thank you so much for coming. Really excited to hear more about CAMP4. Maybe you can start with an introduction, and we can get to questions.

Josh Mandel-BrehmCEO

Great. Yep. Thank you for having us. I think it's our first time here, so we appreciate it. CAMP4 uses antisense oligonucleotides to increase gene expression. The way that we are able to do that is by targeting a new class of RNAs called regulatory RNAs. Every protein-coding gene in our body relies on its own unique and specific set of RNAs, called regulatory RNAs, to control its expression. We've built a platform that allows us to do two very important things. The first is for any protein-coding gene in which we're interested in increasing, we can use our platform to pinpoint the regulatory RNA that's controlling it, and then we can take advantage of state-of-the-art Gen 2 antisense oligonucleotide chemistry to very specifically drug that regulatory RNA and have about a two-fold increase in the associated protein-coding gene's expression.

Matthew TanBiotech Equity Research Associate

Okay. Maybe we can start with your lead program, which is on SYNGAP. I guess, what was the biological rationale with starting with that?

Josh Mandel-BrehmCEO

Yeah. We've been working on this for a bit over six years, and I think the trick with every platform company is finding your sweet spot. Some of the metrics we used for that were, we said, first and foremost, where are antisense oligonucleotides delivered safely and effectively, right? Because we want to buy down as much risk as possible. As I mentioned, we're using chemistry that is already in approved products like SPINRAZA, but in hundreds of clinical trials. Lastly, what we've learned, and I alluded to this, is that we really live in two-fold increases, and that's actually perfectly suited for an entire category of diseases called haploinsufficiencies, where you have one of your two alleles is mutated and no longer functional, so you're only making 50% of what you'd otherwise need to be healthy.

Josh Mandel-BrehmCEO

And as it turns out, the CNS in particular has 30 to 40 haploinsufficiency diseases in regions of the brain that you can absolutely get to via intrathecal delivery of ASOs. Actually, the great majority of them have no approved treatments, and they are massive unmet needs. SYNGAP was a clear choice once we really started to understand it and then when we stacked the data behind it.

Matthew TanBiotech Equity Research Associate

Mm-hmm. Okay. Maybe can you walk us through what sort of preclinical data, what sort of improvements did you see with the SYNGAP?

Josh Mandel-BrehmCEO

Yeah. We like to start at first with patient cells.

Josh Mandel-BrehmCEO

The first thing we do is we looked at iPSC-derived patient cells that replicate, obviously, a haploinsufficient state. What we saw very quickly is that we could restore the remaining allele in those iPSC-derived cells back to a two-fold increase. Essentially, you're bringing the patient theoretically back to a normal state. We're fortunate in that for SYNGAP, there's a very well-organized and strong patient advocacy group.

Josh Mandel-BrehmCEO

which is critical for any rare disease. As a consequence of that, they have actually invested in things like natural history studies, which we will talk about, but also a humanized mouse model. The humanized mouse model is great because it actually has SYNGAP1 patient-derived cells. It is a haploinsufficient mouse, and it actually replicates the disease pretty well in terms of anxiety, learning, and you can actually induce seizures in these mice chemically. We took our human drug candidate, and we tested it at therapeutic level, at levels that would be therapeutic in the clinic. What we saw, which was very encouraging and nobody has done before, is that we could actually reverse all the symptoms of the disease.

Josh Mandel-BrehmCEO

I think that was very powerful. Then lastly, what I would point out is we went into primates. Primates don't replicate the disease. They have two functional alleles, but it allows us to actually deliver the drug intrathecally, which is how we will do it in the clinic, and it is 100% cross-reactive with primates. What I will point out is we saw a statistically significant increase in the SYNGAP gene, and it turns out when you use antisense oligonucleotides against single gene diseases and you see a pharmacodynamic effect like that in monkeys, that tends to translate as well, if not better, in the clinic. That was extremely encouraging for us.

Matthew TanBiotech Equity Research Associate

Okay. That's good to know. I guess maybe we can go to the clinical study, the design, and what you might expect to see.

Josh Mandel-BrehmCEO

Mm-hmm. We took a lot of time to balance, I think, a lot of learnings from previous companies that have used CNS oligos or worked in the DEE space, developmental epileptic encephalopathy space, which is what SYNGAP1 is. What we came up with was a study that, first and foremost, allows us to go directly into patients, so where it is a phase I/II study. We are skipping the SAD phase and going directly into the multiple ascending dose phase. We are starting with the majority of patients who are truly haploinsufficient, so 80% of patients have a mutation that renders them completely haploinsufficient, so those are the patients we are enrolling. Some of the criteria are daily seizures, inability to speak. Effectively, these patients are very sick, ages two to 18 years old, and we are taking a global approach.

Josh Mandel-BrehmCEO

We have approval in four distinct jurisdictions: Argentina, Australia, the U.K., and the EMA. Lastly, I'll point out, we have multiple different controls here. It's a 3-to-1 randomization. Three patients that get a drug, one gets a control. Every patient has their own baseline period, so they're controlled against themselves, and we can also leverage natural history data.

Matthew TanBiotech Equity Research Associate

Okay. In terms of the endpoints, you mentioned seizure and other types of endpoints. What would you expect to see change in this length of study?

Josh Mandel-BrehmCEO

Yeah. Maybe it's important to take a step back very quickly and say that when you have a mutation in SYNGAP1, you have too many receptors in your synapse. As a result of that, you get too much synaptic firing. I think about it as the patient's brain is constantly short-circuiting throughout the day. As a result of that, patients can have hundreds of seizures a day. They barely sleep. They cannot communicate. They're not verbal. They have anger issues. They have motor problems. There's no part of the patient's life or a caregiver's life that's not affected by this disease. We believe because we're acting at essentially the genetic level by allowing the gene to make more SYNGAP, essentially trying to restore patients back to a normal state, that it's possible to have a disease-modifying effect across all of these different domains of the disease.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day